论文部分内容阅读
不稳定型心绞痛(UAP)是介于劳累性稳定型心绞痛,急性心肌梗死(AMI)和猝死(SD)之间的中间状态,病变复杂,预后较严重。低分子肝素是一种新型抗凝剂,本研究探讨低分子肝素治疗UAP的有效性和安全性。资料与方法一、病例选择:1998年11月至1999年7月于我院住院的20例病人,男13例,女7例,平均年龄62.5岁(51～80岁),经详细问病史,体格检查,心电图,心肌酶谱等检查,均符合不稳定型心绞痛。二、治疗方法:低分子肝素由法国罗纳普朗克—乐安公司
Unstable angina pectoris (UAP) is an intermediate state between exertional stable angina pectoris, acute myocardial infarction (AMI) and sudden death (SD), with complicated lesions and severe prognosis. Low molecular weight heparin is a new type of anticoagulant. This study investigated the efficacy and safety of low molecular weight heparin in the treatment of UAP. Materials and methods First, the patient selection: November 1998 to July 1999 in our hospital 20 patients, 13 males and 7 females, average age 62.5 years (51 to 80 years old), after detailed medical history, Physical examination, electrocardiogram, myocardial enzymes and other tests, are in line with unstable angina. Second, the treatment: low-molecular-weight heparin from France Lonoplankton - Le An Company